| Viral Load at week 4 | Viral Load at week 12 | Viral Load at week 8 | Viral Load at week 24 | Adverse events | |
|---|---|---|---|---|---|
| Telaprevir (14 patients) | 71% detectable 29% undetectable | 93% undetectable 7% detectable | Not applicable | Not applicable | 21% skin rash 29% ano-rectal discomfort 43% anaemia |
| Boceprevir (3 patients) | Not applicable | Not applicable | 100% undetectable | 1 undetectable 2 not reached | 100% taste disorder 14% ano-rectal discomfort 14% anaemia |